

Theralase Introduces Low Priced Laser Series

New TLC-900 Laser Series Offers Theralase's Renowned Clinical Performance at Lower Prices

Toronto, Ontario – November 17, 2011, Theralase Technologies Inc. (TSX-V: TLT) announced today that it has launched a new version of the high performance Theralase TLC-1000 therapeutic medical laser series, known as the Theralase TLC-900 series, which effectively eliminates the controller and allows the practitioner to operate the laser probes independently. This TLC-900 system allows the practitioner the ability to benefit from the high performance Theralase laser system technology, albeit with less features and versatility than the TLC-1000 series, but at an overall cost savings.

Roger Dumoulin-White, President and CEO of Theralase stated, "The Theralase TLC-900 series has been designed by our engineering team for practitioners, who have specific applications of our technology in mind. By selecting only one of our 3 styles of laser probes and not requiring the ability to switch back and forth between laser probes, the practitioner is able to eliminate the controller as well as the laser probes that are not required, thus lowering the overall purchase price of the product. Practitioners are still able to utilize the same superpulsed dual wavelength laser technology, with its high patient efficacy and low hands-on treatment time, but at a more economical price point. We introduced this new technology to open up our product line to allow practitioners the ability to integrate state-of-the-art Theralase therapeutic laser technology into their practice, but without all of the features or all of the laser probes of the TLC-1000 laser series. Now every medical practitioner can add a high performing Theralase therapeutic laser into their practice to treat chronic pain, inflammation, wound healing and neural muscular-skeletal conditions, at a more cost effective price. Theralase believes that this will open up the therapeutic laser market and give practitioners the ability to choose a high performing product, such as the Theralase, at the same price points as lower end, non-effective, competitive technology."

Theralase has published a White Paper covering the science and cellular mechanisms of how Low Level Laser Therapy (LLLT) works. It may be easily accessed by going to www.thermalase.com/www/whitepapers.php to download the free publication.

About Theralase Technologies Inc.

Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target

and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.thermalase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information

Roger Dumoulin-White
President & CEO,
416-447-8455 ext. 225
rwhite@thermalase.com

Greg Bewsh
Director of Investor Relations,
416-447-8455 ext. 262
gbewsh@thermalase.com